Associate Director, International Market Access, Neuroscience, Migraine

Company Description

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on X, Facebook, Instagram, YouTube, LinkedIn and Tik Tok.

Job Description

International Market Access & Pricing: Lead International market access strategies and prepare priority migraine assets for launch.

This position will lead to the international launch of migraine assets in new indications reporting into Migraine & Toxins Lead (Director).

• Core responsibilities include developing critical launch tools - Payor Value Message, Payor objection handler sand negotiation strategies to prepare affiliates for launch. This position will lead the Access Strategic Imperative group and work closely with the International Brand Team (INBT).
• Additionally, the applicant will leverage their payer knowledge alongside expertise of Evidence Based Medicine to shape pivotal development programs for enterprise critical launch assets.

Specific Responsibilities Include:

• Addressing reimbursement, access (PRA) potential across international key markets, including the EU5, CAN, JPN, AUS, BRA and China
• Development of key strategic market access deliverables aligned with the overall Neurosciences Strategy and in line with AbbVie’s framework and the asset playbook.
• Influence clinical development programs to ensure endpoints and trial design are incorporated that will optimize price, reimbursement and ultimately patient access globally.
• Proactively ensure reimbursement perspective is incorporated into early brand plans, disease area strategies and portfolio strategies throughout key clinical development milestones and strategic commercial decisions for future indications
• Inform key asset milestone decisions by identifying access trade-offs (price, speed, population).
• Collaborate with GHEOR, Clinical Evidence & Outcom